A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

A Systematic Review of Lopinavir Therapy for SARS Coronavirus and MERS Coronavirus–A Possible Reference for Coronavirus Disease‐19 Treatment Option

(2020) Tian‐Tian Yao et al.   JOURNAL OF MEDICAL VIROLOGY

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

(2020) Lirong Zou et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia

(2020) Qun Li et al.   NEW ENGLAND JOURNAL OF MEDICINE

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

(2020) Xiaolong Tian et al.   Emerging Microbes & Infections

Novel Coronavirus Outbreak in Wuhan, China, 2020: Intense Surveillance Is Vital for Preventing Sustained Transmission in New Locations

(2020) Robin N. Thompson   Journal of Clinical Medicine

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

(2020) Philippe Gautret et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Randomized Clinical Trials and COVID-19

(2020) Howard Bauchner et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Interpreting Diagnostic Tests for SARS-CoV-2

(2020) Nandini Sethuraman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

(2020) Ivan Fan-Ngai Hung et al.   LANCET

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

(2020) Yeming Wang et al.   LANCET

Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study

(2020) Qifang Bi et al.   LANCET INFECTIOUS DISEASES

Virological assessment of hospitalized patients with COVID-2019

(2020) Roman Wölfel et al.   NATURE

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2

(2020) Vincent J. Munster et al.   NATURE

Temporal dynamics in viral shedding and transmissibility of COVID-19

(2020) Xi He et al.   NATURE MEDICINE

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

(2020) Joshua Geleris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Compassionate Use of Remdesivir for Patients with Severe Covid-19

(2020) Jonathan Grein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

(2020) Barry Rockx et al.   SCIENCE

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

(2020) Hongzhou Lu   BioScience Trends

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)

(2020) Ricarda M. Hoffmann et al.   Scientific Reports

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

(2020) Philippe Gautret et al.   Travel Medicine and Infectious Disease

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

(2020) Wei Tang et al.   BMJ-British Medical Journal

Prevalence of Asymptomatic SARS-CoV-2 Infection

(2020) Daniel P. Oran et al.   ANNALS OF INTERNAL MEDICINE

A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies

(2020) Ahmed O. Hassan et al.   CELL

Distribution of Transmission Potential During Nonsevere COVID-19 Illness

(2020) Nabin K Shrestha et al.   CLINICAL INFECTIOUS DISEASES

Estimates of the severity of coronavirus disease 2019: a model-based analysis

(2020) Robert Verity et al.   LANCET INFECTIOUS DISEASES

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

(2020) Francois-Xavier Lescure et al.   LANCET INFECTIOUS DISEASES

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

(2020) Brandi N. Williamson et al.   NATURE

Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody

(2020) Mangaiarkarasi Asokan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti–HIV-1 IgG1 antibodies in vivo

(2020) Pengfei Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In-host Mathematical Modelling of COVID-19 in Humans

(2020) Esteban A. Hernandez-Vargas et al.   ANNUAL REVIEWS IN CONTROL

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19

(2020) Christoph D. Spinner et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response

(2020) Ashish Goyal et al.   Science Advances

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

(2020) Alexandra Schäfer et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Phillip D Monk et al.   Lancet Respiratory Medicine

A dynamical motif comprising the interactions between antigens and CD8 T cells may underlie the outcomes of viral infections

(2019) Subhasish Baral et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies

(2017) Katharine Best et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection

(2017) Yoshiki Koizumi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Modelling Ebola virus dynamics: Implications for therapy

(2016) Alexey Martyushev et al.   ANTIVIRAL RESEARCH

Estimating biologically relevant parameters under uncertainty for experimental within-host murine West Nile virus infection

(2016) Soumya Banerjee et al.   Journal of the Royal Society Interface

Viral Load Kinetics of MERS Coronavirus Infection

(2016) Myoung-don Oh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quantifying the effect of Vpu on the promotion of HIV-1 replication in the humanized mouse model

(2016) Hiroki Ikeda et al.   Retrovirology

Post-treatment control of HIV infection

(2015) Jessica M. Conway et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A mechanistic theory to explain the efficacy of antiretroviral therapy

(2014) Sarah B. Laskey et al.   NATURE REVIEWS MICROBIOLOGY

Identifying viral parameters from in vitro cell cultures

(2012) Shingo Iwami et al.   Frontiers in Microbiology

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

(2008) Lin Shen et al.   NATURE MEDICINE